Your browser doesn't support javascript.
loading
[Post-marketing intensive safety monitoring of Injection of Xuesaitong (lyophilized) in 30097 cases].
Xin-Yao, Jin; Ke-Yi, Wang; Jing-Bo, Zhai; Chun-Xiang, Liu; Hui, Wang; Zhi, Liu; Wen-Tai, Pang; Hu-Cheng, Wang; Nan, L I; Jun-Hua, Zhang; Wen-Ke, Zheng.
Affiliation
  • Xin-Yao J; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
  • Ke-Yi W; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
  • Jing-Bo Z; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
  • Chun-Xiang L; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
  • Hui W; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
  • Zhi L; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
  • Wen-Tai P; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
  • Hu-Cheng W; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
  • Nan LI; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
  • Jun-Hua Z; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
  • Wen-Ke Z; Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
Zhongguo Zhong Yao Za Zhi ; 45(20): 5029-5033, 2020 Oct.
Article de Zh | MEDLINE | ID: mdl-33350279
ABSTRACT
To investigate the safety of Injection of Xuesaitong(lyophilized) in clinical "real world" application, including the types, incidence, as well as the severity and treatment measures of adverse reactions/adverse events. This will serve as a basis for hospitals and enterprises to develop risk control measures. A prospective, multi-center, and large-sample hospital centralized monitoring method was used to conduct post-marketing safety monitoring of Injection of Xuesaitong(lyophilized) in medical institutions nationwide. Paper case report forms were adopted to collect general information, medication and adverse reaction information of patients using Injection of Xuesaitong(lyophilized). Data analysis was performed by using SAS 9.1 software. The study included 79 hospitals with 30 097 patients. 199 cases of adverse events were found in patients administered with Injection of Xuesaitong(lyophilized), a total of 206 times. Among 199 cases, 40 of them showed adverse reactions, accounting for an overall incidence of 0.13% and 95%CI[0.09%,0.17%], which was an occasional grade. There were 38 cases of mild adverse reactions, accounting for 95.0%, 2 cases of moderate adverse reactions, accounting for 5.0%. Adverse reaction symptoms were relieved in six patients, accounting for 15.0% of the total number of adverse reactions, adverse reaction symptoms disappeared in 34 cases, with an overall percentage of 85.0%. The results of the study showed the adverse reactions in patients using Injection of Xuesaitong(lyophilized) were rare and mild, with a good prognosis. Therefore, clinical administration of Injection of Xuesaitong(lyophilized) is relatively safe.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Saponines / Médicaments issus de plantes chinoises Type d'étude: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: Zh Journal: Zhongguo Zhong Yao Za Zhi Sujet du journal: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Année: 2020 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Saponines / Médicaments issus de plantes chinoises Type d'étude: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: Zh Journal: Zhongguo Zhong Yao Za Zhi Sujet du journal: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Année: 2020 Type de document: Article Pays d'affiliation: Chine